Invitrocue Releases March 2019 Quarterly And Appoints New Advisor
Innovative life sciences company Invitrocue Limited (ASX:IVQ) (“Invitrocue” or “the Company”) is pleased to provide its Appendix 4C cash flow statement for the quarter ended March 31, 2019 (Q3 FY19) and to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.
Read 4C Quarterly Report here
Read about the new appointment here
About Invitrocue
Invitrocue Limited (ASX:IVQ) is an innovative life sciences company that specialises in developing ground-breaking 3D cell-based models derived from liver and tumour tissues. Headquartered in Singapore and with operations in Australia, China, Hong Kong and Germany, Invitrocue’s Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalised clinical decisions.
By enabling assessments of the best ways for drugs to be developed, Invitrocue creates better, faster and more affordable disease treatments, that work towards the company’s goal of creating a healthier society by providing patients with the best possible care. To learn more please visit: https://www.invitrocue.
Company Enquiries
Martin Bach
VP Operations
p: +65 8457 1820
e: martind.bach@invitrocue.com
Media & Investor Enquiries
The Capital Network
Julia Maguire
p: + 61 (0) 419 815 386
e: julia@thecapitalnetwork.